Research tools
Biopsy articles covering tissue sampling, diagnosis, inflammation assessment, dysplasia surveillance, and IBD research findings. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
21 articles
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.
The project aims to enable simultaneous RNA-level profiling of microbes and host cells from human biopsies, which could reveal early microbial and host gene-expression patterns linked to subclinical Crohn’s disease and...
Distinguishing IBD from gastrointestinal tuberculosis is challenging in regions where GITB is common; histologic markers like basal plasmacytosis and eosinophilia on mucosal biopsy could help guide diagnosis when...
An organoid platform that models epithelial injury and recovery could help researchers test treatments and biomarkers more precisely and at scale, accelerating work relevant to Crohn’s disease and other IBDs.
GI infections—especially CMV—were common in this study and much more frequent in acute severe UC than in remission, suggesting testing for infections can change diagnosis and management during severe flares.
Pouchitis is a common complication after IPAA and noninvasive tools to detect inflammation could make monitoring easier and less burdensome than repeated pouchoscopy. This trial tested whether intestinal ultrasound can...
AI models that combine CTE/MRE imaging with clinical and molecular data could improve objective classification of small-bowel Crohn's disease and help predict which patients are likely to respond to medical therapy...
Patients and clinicians may care because the study suggests contrast-enhanced CT can reliably detect and localize IBD, including transmural and small-bowel disease that biopsies miss, which could affect diagnostic...
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
EEN is being evaluated as a non‑pharmacologic induction therapy in adults with active and complicated Crohn’s disease; results could inform whether EEN helps induce remission, improve nutrition, and impact inflammation...
If confirmed, an endocytoscopic appearance that corresponds to a specific miRNA and chemokine pattern could help clinicians assess mucosal inflammation during colonoscopy and prioritize biopsies or treatment decisions...
People with IBD may have a higher-than-expected rate of biopsy-confirmed celiac disease in this Northern Indian cohort, and standard anti-tTG blood tests can be falsely positive in IBD. Confirmatory duodenal biopsy is...
People with UC can develop severe neutrophilic skin complications like Sweet’s syndrome that may reflect active bowel inflammation even when recent tests suggested remission.
This trial tests etrasimod (an S1P receptor modulator) specifically in older adults with active ulcerative colitis — a group often underrepresented in IBD trials. Results could inform safety and short-term remission...
Granulomas are a classic histologic feature of Crohn’s disease, so patients and clinicians may wonder whether their presence predicts worse disease or different treatment needs. This review shows existing studies are...
CMV reactivation can worsen outcomes in active UC and influence treatment choices; clinicians and patients may benefit from additional, easy-to-measure markers that flag higher risk of tissue CMV and prompt targeted...
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
The atlas maps which genes and cell types are different in Crohn's disease, offering clues about why inflammation persists and pointing to specific immune pathways (like JAK/STAT) that are already drug targets. The...
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
